Who makes PF-07284890 Treatment A?

PF-07284890 Treatment A is developed by Pfizer.

What development phase is PF-07284890 Treatment A in?

PF-07284890 Treatment A is in Phase 1.

Last reviewed 2026-04-19 · How we verify

PF-07284890 Treatment A

Pfizer · Phase 1 active Small molecule

At a glance

Generic name	PF-07284890 Treatment A
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (PHASE1)
A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-07284890 Treatment A CI brief — competitive landscape report
PF-07284890 Treatment A updates RSS · CI watch RSS
Pfizer portfolio CI